Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.44 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.38 |
| ▸ | LPL | P06858 | 4/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1337551 | 0.80 | ATM (0.41) | LPLLIPGPRMT5WDR77IDO1 | |
| SCHEMBL1337645 | 0.79 | LPL (0.42) | LPLLIPGPRMT5WDR77 | |
| SCHEMBL22438423 | 0.76 | LPL (0.38) | LPLLIPGPRMT5WDR77EGFR | |
| SCHEMBL2220082 | 0.75 | IMPDH2 (0.44) | IMPDH2CCNT1CDK9HASPINLPL | |
| SCHEMBL1337282 | 0.74 | LPL (0.50) | LPLLIPG | |
| SCHEMBL15617180 | 0.74 | LIPG (0.53) | IMPDH2HASPINLPLLIPGPRMT5 | |
| SCHEMBL17588945 | 0.74 | PRMT5 (0.42) | LPLLIPGPRMT5WDR77IDO1 | |
| SCHEMBL24214891 | 0.74 | HIF1A (0.39) | LIPGPRMT5WDR77CA1CA2 | |
| SCHEMBL15897087 | 0.74 | ALDH1A1 (0.56) | ALDH1A1CYP2C19KDM4EMAPTLIPG | |
| SCHEMBL3070024 | 0.74 | NR4A2 (0.58) | MAPTPRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-8785438-B2 | Imidazopyridin-2-one derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| US-20130338156-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-12-19 | — | — | US | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| US-8436012-B2 | Imidazopyridin-2-one derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| EP-2308877-A1 | IMIDAZOPYRIDIN-2-ON DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-20110082138-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-07 | — | — | US | disclosed |
| EP-2303886-A2 | PI3K/M TOR INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010008847-A2 | PI3K/M TOR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | WO | disclosed |
| EP-2001480-A2 | INDAZOLE COMPOUNDS | Abbott Laboratories (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| WO-2007117465-A2 | INDAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117465-A2 | INDAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082138-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | MTOR, MAPKAP1, RICTOR | ALDH1A1 2312/4885CYP1A2 1450/4885CYP2C19 766/4885 |
| US-20070282101-A1 | Indazole compounds | CYP3A43, CYP3A7, UGT1A1 | ALDH1A1 89/4885CYP1A2 15/4885CYP2C19 4/4885 |
| US-20130338156-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | MTOR, MAPKAP1, RICTOR | ALDH1A1 2312/4885CYP1A2 1450/4885CYP2C19 766/4885 |
| US-20120053345-A1 | Indazole Compounds | CYP3A43, CYP3A7, UGT1A1 | ALDH1A1 89/4885CYP1A2 15/4885CYP2C19 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.